Edinburgh Research Explorer

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer

Research output: Contribution to journalArticle

  • Marsela Braunstein
  • Linda Liao
  • Nicola Lyttle
  • Nazleen Lobo
  • Karen J. Taylor
  • Paul M. Krzyzanowski
  • Irina Kalatskaya
  • Cindy Q. Yao
  • Lincoln D. Stein
  • Paul C. Boutros
  • Christopher J. Twelves
  • Richard Marcellus
  • John M S Bartlett
  • Melanie Spears

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

    Final published version, 1.8 MB, PDF document

    Licence: Creative Commons: Attribution (CC-BY)

Original languageEnglish
Article number16
JournalBreast Cancer Research
Issue number1
Publication statusPublished - 6 Feb 2016


Background: Drug resistance in breast cancer is the major obstacle to effective treatment with chemotherapy. While upregulation of multidrug resistance genes is an important component of drug resistance mechanisms in vitro, their clinical relevance remains to be determined. Therefore, identifying pathways that could be targeted in the clinic to eliminate anthracycline-resistant breast cancer remains a major challenge. Methods: We generated paired native and epirubicin-resistant MDA-MB-231, MCF7, SKBR3 and ZR-75-1 epirubicin-resistant breast cancer cell lines to identify pathways contributing to anthracycline resistance. Native cell lines were exposed to increasing concentrations of epirubicin until resistant cells were generated. To identify mechanisms driving epirubicin resistance, we used a complementary approach including gene expression analyses to identify molecular pathways involved in resistance, and small-molecule inhibitors to reverse resistance. In addition, we tested its clinical relevance in a BR9601 adjuvant clinical trial. Results: Characterisation of epirubicin-resistant cells revealed that they were cross-resistant to doxorubicin and SN-38 and had alterations in apoptosis and cell-cycle profiles. Gene expression analysis identified deregulation of histone H2A and H2B genes in all four cell lines. Histone deacetylase small-molecule inhibitors reversed resistance and were cytotoxic for epirubicin-resistant cell lines, confirming that histone pathways are associated with epirubicin resistance. Gene expression of a novel 18-gene histone pathway module analysis of the BR9601 adjuvant clinical trial revealed that patients with low expression of the 18-gene histone module benefited from anthracycline treatment more than those with high expression (hazard ratio 0.35, 95 % confidence interval 0.13-0.96, p = 0.042). Conclusions: This study revealed a key pathway that contributes to anthracycline resistance and established model systems for investigating drug resistance in all four major breast cancer subtypes. As the histone modification can be targeted with small-molecule inhibitors, it represents a possible means of reversing clinical anthracycline resistance. Trial registration: ClinicalTrials.gov identifier NCT00003012. Registered on 1 November 1999.

    Research areas

  • Anthracycline resistance, Breast cancer, Clinical trial, Gene expression, Histone, Small-molecule inhibitors

Download statistics

No data available

ID: 25106134